Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for
the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50
years.